A preliminary report on the use of transfer factor for treating stage D3 hormone-unresponsive metastatic prostate cancer
| Autor: | D. Menniti, Maver P, P. Romagnoli, Viza D, Riolo U, C De Vinci, A. Palareti, E. Aiello, G. Pizza, Cuzzocrea D, P Zucchelli, V. Fornarola, G. Corrado, Dragoni E, G LoConte |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Male
Oncology medicine.medical_specialty Neoplasms Hormone-Dependent Transfer Factor Adenocarcinoma Prostate cancer Prostate Internal medicine medicine Humans Neoplasm Metastasis Stage (cooking) Survival rate Aged Neoplasm Staging Pharmacology Immunity Cellular Hematology business.industry Prostatic Neoplasms Cancer Middle Aged medicine.disease Surgery Clinical trial medicine.anatomical_structure Urinary Bladder Neoplasms Cell Migration Inhibition business Intramuscular injection Follow-Up Studies |
| Zdroj: | Biotherapy. 9:123-132 |
| ISSN: | 1573-8280 0921-299X |
| DOI: | 10.1007/bf02628669 |
| Popis: | As conventional treatments are unsuccessful, the survival rate of stage D3 prostate cancer patients is poor. Reports have suggested the existence of humoral and cell-mediated immunity (CMI) against prostate cancer tumour-associated antigens (TAA). These observations prompted us to treat stage D3 prostate cancer patients with an in vitro produced transfer factor (TF) able to transfer, in vitro and in vivo, CMI against bladder and prostate TAA. Fifty patients entered this study and received one intramuscular injection of 2-5 units of specific TF monthly. Follow-up, ranging from 1 to 9 years, showed that complete remission was achieved in 2 patients, partial remission in 6, and no progression of metastatic disease in 14. The median survival was 126 weeks, higher than the survival rates reported in the literature for patients of the same stage. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink